Concepedia

Author

Alberto Zaniboni

Fondazione Poliambulanza Istituto OspedalieroORCID

Also Known As

A Zaniboni, A. Zaniboni, Alberto Zaniboni, Enrico Aitini, Nicoletta Donadello, S Barni, Sara Lonardi, Zaniboni Alberto, Zaniboni, A.

495

Publications

16.2K

Citations

57

H-Index

84

Concepts

All Affiliations

Fondazione Poliambulanza Istituto OspedalieroIstituti di Ricovero e Cura a Carattere ScientificoIstituto Oncologico VenetoAzienda Ospedaliera Universitaria PisanaFondazione IRCCS Istituto Nazionale dei Tumori
AZ

About

Alberto Zaniboni is an author at Fondazione Poliambulanza Istituto Ospedaliero specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

32

81

5K

2

Health Sciences

15

26

865

3

Nursing

1

1

95

4

Public Health

1

1

56

5

Cell Biology

1

1

61

Alberto Zaniboni

×

152

Publications

13.1K

Citations

51

H-Index

YearCitations

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

Daniel J. Sargent, Silvia Marsoni, Geneviève Monges,

Journal of Clinical Oncology

2010

1.6K

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone,

New England Journal of Medicine

2015

1.4K

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti,

The Lancet Oncology

2015

1.1K

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Fotios Loupakis, Chiara Cremolini, Gianluca Masi,

New England Journal of Medicine

2014

1.1K

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

Christophe Louvet, Roberto Labianca, Pascal Hammel,

Journal of Clinical Oncology

2005

948

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti,

British Journal of Cancer

2020

315

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini,

The Lancet Oncology

2020

309

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

Eduardo Díaz‐Rubio, Javier Sastre, Alberto Zaniboni,

Annals of Oncology

1998

227

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer

Marco Bregni, Anna Dodero, Jacopo Peccatori,

Blood

2002

206

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Chiara Cremolini, Fotios Loupakis, C. Antoniotti,

Annals of Oncology

2015

191

Page 1